Cutaneous amyloid is a biomarker in early ATTRv neuropathy and progresses across disease stages
Sign Up to like & getrecommendations! Published in 2022 at "Annals of Clinical and Translational Neurology"
DOI: 10.1002/acn3.51636
Abstract: To determine the sensitivity and specificity of cutaneous amyloid deposition in relation to patient‐reported measures in the earliest disease stage of hereditary ATTR amyloidosis (ATTRv). read more here.
Keywords: biomarker early; disease; cutaneous amyloid; amyloid biomarker ... See more keywords